Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

Development of MRI Protocols and Associated Neuro-physiological Explorations in Healthy and Pathological Subjects

NCT05036629 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2021-09-09
Last updated
2026-10-02

Condition(s) studied

MRISequence OptimizationPhysiological Measurement

Investigational drug(s) / intervention(s)

MRI Protocol

MRI Protocol: Eye-tracker Eyelink (eye movements) BIOPAC : (electrodermal resistance) INVIVO Precess : breathing, arterial pressure, pulse, * NIRS Oxymon artinis medical system * tES (transcranial electrical stimulation, Neuroelectrics)

Study summary

IRMaGe is a Joint Service Unit (UMS) which provides users of brain exploration equipment (clinical MRI and preclinical, TMS, EEG, NIRS and metabolomics). The methods available on this equipment are intended to evolve according to the most recent discoveries and this protocol aims to frame the developments necessary around clinical MRI for IRMaGe can continue to offer tools at the cutting edge of technology.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Participants with normal or corrected vision * Participants affiliated to a social security scheme or beneficiaries of such a scheme * Participants with French as their mother tongue * Participants who have given the signed informed consent before carrying out any procedure related to the study. * Volunteer patients will be recruited as part of their follow-up at the CHU. Their pathology will be in agreement with that of the research protocol to be optimized. Exclusion Criteria: Criteria relating to contraindications to the explorations provided for by the MRI protocol: * metallic glitter in the eyes * retinal operation * claustrophobia * wearer of pacemaker or cardiac defribrillator or vascular clip or prosthesis cardiac or insulin pump or implanted device to deliver medication or hearing implant or prosthesis or vascular shunt or paragraph or screws, plate metal or tattoo or piercing or implanted metal object or lead shot hunt * Alcohol ingestion before the examination * Pregnant, lactating and parturient women * Major protected by law * Participants under administrative or judicial supervision * Participation in another ongoing study if the study may interfere with participation in the protocol MAP-IRMaGe.

Primary outcome measure(s)

  • Diffusion Tensor Imaging Images — 1 to 3 hours
    DTi sequences on IRM Achieva 3.0T dStream Philips
  • BOLD Signal — 1 to 3 Hours
    EPI sequences during cognitive protocol on IRM Achieva 3.0T dStream Philips
  • Anatomical Images — 1 to 3 hours
    Anatomical MR sequences on IRM Achieva 3.0T dStream Philips

Trial sites (1)

FacilityCityRegionStatus
Unité Mixte de Service IRMaGe US 017 La Tronche France Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05036629 on ClinicalTrials.gov ↗ ← All trials in France